CD38-targeting antibodies in multiple myeloma

Autor: Noemi Anna Nagy, Pieter L Lindenbergh, Maria Themeli, Sonja Zweegman, Henk M. Lokhorst, Richard W.J. Groen, Patty Bosman, Jhon Marin Soto, Louise Nieuwenhuis, Tuna Mutis, Inger S. Nijhof, Niels W.C.J. van de Donk, Claudia Stege, Kristine A Frerichs, Marloes E.C. Broekmans

Publikováno v: Expert Review of Clinical Immunology, 14(3), 197-206. Taylor and Francis Ltd.
Frerichs, K A, Nagy, N A, Lindenbergh, P L, Bosman, P, Marin Soto, J, Broekmans, M, Groen, R W J, Themeli, M, Nieuwenhuis, L, Stege, C, Nijhof, I S, Mutis, T, Zweegman, S, Lokhorst, H M & van de Donk, N W C J 2018, ' CD38-targeting antibodies in multiple myeloma : mechanisms of action and clinical experience ', Expert Review of Clinical Immunology, vol. 14, no. 3, pp. 197-206 . https://doi.org/10.1080/1744666X.2018.1443809

INTRODUCTION: Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients who developed disease that is r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3affec0a66d2c9094e0a1b0a3c48c84
https://doi.org/10.1080/1744666x.2018.1443809